Clinical trials: Sirolimus, active
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Pulmonary Fibrosis, COVID-19 Pneumonia
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
- Conditions
- Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
- Trial name
- NCT04948203
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis…
- Trial name
- PTCYGVHD (NCT06799195)
- Testing
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Nebraska
Advanced Breast Cancer
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR…
- Trial name
- NCT07173556
- Testing
- QLC1401
- Volunteers
- 96 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)
- Trial name
- NCT07796620
- Testing
- Sirolimus, Ruxolitinib, MMF
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of the combination vorinostat given in combination with either sirolimus, everolimus or temsirolimus that can be given to patients with advanced…
- Trial name
- NCT01087554
- Testing
- Sirolimus, Vorinostat, Everolimus
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- M.D. Anderson Cancer Center
Coronary Artery Disease, Diffuse Coronary Artery Disease
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
The primary objective of the study is to assess the safety and the efficacy of a hybrid percutaneous coronary intervention (PCI) strategy combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik…
- Conditions
- Coronary Artery Disease, Diffuse Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
- Trial name
- BIOHYBRID (NCT06710210)
- Testing
- PCI with a bioresorbable scaffold and drug-coated balloon(s), PCI with drug-eluting stent(s)
- Where
- 4 sites in Switzerland
- Volunteers
- 150 people
- Sponsor
- University Hospital, Geneva
Advanced Rare Tumours
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
- Trial name
- NCT01396408
- Testing
- Sunitinib, Temsirolimus
- Where
- 17 sites in Canada
- Volunteers
- 137 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
This is a multi-center,randomized,phase 3 clinical trial. In the study, HER2-positive metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after progression on trastuzumab are enrolled and…
- Trial name
- NCT04736589
- Testing
- Inetetamab, Rapamycin, Pyrotinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking Union Medical College
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Inclusion Body Myositis
Phase III Trial of Sirolimus in IBM
The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ transplantation and works by blocking the activity of T effector cells but preserving T regulatory cells, as well as by inducing autophagy…
- Trial name
- NCT04789070
- Testing
- Sirolimus
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 140 people
- Sponsor
- University of Kansas Medical Center
Renal Cell Carcinoma
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by…
- Trial name
- CLEAR (NCT02811861)
- Testing
- Lenvatinib, Everolimus, Pembrolizumab
- Where
- 183 sites in United States, Australia and 18 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Systemic Lupus Erythematosus
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
This is a multi-center, double-blinded, randomized, placebo-controlled, phase 3 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.
- Trial name
- SIRIUS (NCT04582136)
- Testing
- Sirolimus
- Where
- 6 sites in China
- Volunteers
- 146 people
- Sponsor
- Chinese SLE Treatment And Research Group
Peripheral Arterial Disease
Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion.
- Trial name
- NCT07122167
- Testing
- Peripheral Drug-eluting Stent System
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- MDCECRO LLC
Kidney Transplant Failure and Rejection
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
Background: Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system…
- Trial name
- STARR (NCT03955172)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Familial Platelet Disorder, Hematopoietic
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
- Trial name
- NCT06261060
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Advanced Solid Tumors
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor.
- Trial name
- NCT07241936
- Testing
- sirolimus (albumin-bound), DP303c, SYS6043
- Where
- China
- Volunteers
- 444 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Leigh Syndrome
Sirolimus for Leigh Syndrome
The purpose of this study is to evaluate the safety and efficacy of the drug Sirolimus in participants with Leigh syndrome.
- Trial name
- NCT06843811
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Matthew Demczko